Trial
NCT03389893
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
Regeneron Pharmaceuticals; Sanofi; Atopic Dermatitis Research Network; Rho Federal Systems Division, Inc.
Condition
Atopic Dermatitis (AD)
Intervention
Dupilumab
Why stopped
Due to inability to meet accrual goals within the funding period.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-04